Home
Applications
- Indications
Business
Technology
Investors
News
About Us
Contact Us

OBD launches major Diabetes epigenetics programme in Malaysia to ascertain who is at risk for Type 2 Diabetes.

April 21, 2016

|By Catia Gaspar

Check out the news in The Diabetes Research & Wellness Foundation

Recent Posts

Final Results for year ended 30 September 2019
Laboratory Technician (full-time)
Development and validation of baseline predictive biomarkers for response to immuno-checkpoint treatments in the context of multiline and multitherapy cohorts using EpiSwitch™ epigenetic profiling
Development and validation of baseline predictive biomarkers for response to avelumab in second-line (2L) non-small cell lung cancer(NSCLC) using EpiSwitch™ epigenetic profiling
Oxford BioDynamics’ EpiSwitch™ Featured in Presentations on Development and Validation of Blood-Based Predictive Biomarkers in Immune Checkpoint Inhibitor Programs

Archives

Categories

Episwitch Publication
Events
Jobs
Milestones
People
Publications
Uncategorized

Meta

Log in
Entries RSS
Comments RSS
WordPress.org

Prev
Next

Terms of Use
Site Map

Privacy Policy
Cookies Policy

Regulated and Licensed by Human Tissue Authority
License No. 12571

© 2002-2018 Oxford Biodynamics Plc

We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with this.Ok Read more